NPI: 1932211851 · MONTICELLO, MS 39654 · Critical Access Hospital · NPI assigned 08/31/2006
Authorized official ROWLEY, CHARLA controls 20+ related entities in our dataset. Read more
| Authorized Official | ROWLEY, CHARLA (CEO) |
| NPI Enumeration Date | 08/31/2006 |
Other providers sharing the same authorized official: ROWLEY, CHARLA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 8,681 | $385K |
| 2019 | 7,302 | $367K |
| 2020 | 4,863 | $230K |
| 2021 | 8,307 | $366K |
| 2022 | 10,823 | $443K |
| 2023 | 12,314 | $428K |
| 2024 | 10,004 | $353K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 7,714 | 5,978 | $836K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 3,632 | 2,838 | $448K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,431 | 1,118 | $196K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,052 | 1,757 | $166K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,238 | 1,045 | $117K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,607 | 1,121 | $78K |
| 71045 | Radiologic examination, chest; single view | 2,198 | 1,860 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,812 | 1,246 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,158 | 1,819 | $67K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 696 | 563 | $66K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2,450 | 2,054 | $65K |
| 70450 | Computed tomography, head or brain; without contrast material | 662 | 562 | $51K |
| 71046 | Radiologic examination, chest; 2 views | 1,227 | 1,041 | $51K |
| 80053 | Comprehensive metabolic panel | 5,644 | 4,575 | $46K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,230 | 983 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6,356 | 5,088 | $33K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,221 | 1,043 | $28K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 154 | 75 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 868 | 726 | $20K |
| 83880 | 1,188 | 967 | $18K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 939 | 789 | $11K |
| 84484 | 1,449 | 1,164 | $9K | |
| 36415 | Collection of venous blood by venipuncture | 3,101 | 2,376 | $9K |
| 81001 | 3,690 | 3,143 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | 571 | 504 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | 219 | 187 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 42 | 36 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 28 | 24 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 757 | 657 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 58 | 53 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13 | 12 | $3K |
| 87186 | 474 | 399 | $3K | |
| 82553 | 349 | 307 | $2K | |
| 81025 | 317 | 273 | $2K | |
| 87634 | 35 | 31 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 54 | 51 | $1K |
| 80305 | 129 | 99 | $844.74 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 76 | 66 | $717.60 |
| 87088 | 144 | 131 | $708.44 | |
| 73610 | 13 | 12 | $707.72 | |
| 80061 | Lipid panel | 116 | 89 | $697.32 |
| Q3014 | Telehealth originating site facility fee | 27 | 27 | $603.44 |
| 83036 | Hemoglobin; glycosylated (A1C) | 119 | 102 | $596.18 |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 122 | 77 | $555.32 |
| 87040 | 102 | 57 | $424.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,032 | 845 | $369.77 |
| 82550 | 108 | 82 | $335.91 | |
| 83735 | 108 | 73 | $314.43 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 804 | 666 | $299.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 666 | 567 | $296.64 |
| 86140 | 74 | 64 | $253.24 | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19 | 12 | $230.59 |
| 85027 | 65 | 52 | $188.81 | |
| 83605 | 111 | 87 | $180.56 | |
| 83690 | 36 | 26 | $173.49 | |
| 82948 | 67 | 28 | $156.92 | |
| 85651 | 49 | 42 | $143.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 438 | 356 | $112.51 |
| 84145 | 14 | 12 | $1.64 | |
| A9270 | Non-covered item or service | 193 | 33 | $0.32 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 12 | 12 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 16 | 12 | $0.00 |